Triple negative breast cancer (TNBC) is a particularly aggressive form of breast cancer. Patients are treated with chemotherapy, which can cause debilitating side effects. A new start-up called SynXT Therapeutics aims to bring some hope to those patients. Founded by Chemistry & Biochemistry Professor Xiaohua Peng and her former PhD student Taufeeque Ali, the company is developing a novel anti-cancer drug that has had promising results in treating triple-negative breast cancer without harsh side effects. The most novel part of the drug is how it partners with Vitamin C to selectively target cancer cells while leaving healthy cells intact. SynXT Therapeutics has won numerous grants to support their work, and recently won a second Bridge Grant from the UWM Research Foundation.
Chemistry professor and UWM alum co-found a start-up to develop a breast cancer treatment
